PapersPMID:17987126
Effects of a flaxseed-derived lignan supplement in type 2 diabetic patients: a randomized, double-blind, cross-over trial.
- findings
- 2
- compound
- 1
- endpoints
- 2
- Study, every finding
- crossover · 3 months
- Dose studied, every finding
- three capsules (0.6 g each) daily, 360 mg isolated flaxseed lignan per day, 12 weeks
- Population, every finding
- 68 adults with type 2 diabetes and mild hypercholesterolaemia (LDL-C 2.9 mmol/L or above), 60 on oral hypoglycaemic agents; 12-week treatment periods separated by an 8-week washout
No finding here moved its endpoint.
What did not
How to read these marks →“Compared with the values after 12-week placebo treatment, HbA1c was significantly reduced with lignan supplementation, whereas changes in HOMA-IR, fasting glucose and insulin concentrations were not significantly different between the two treatments.”
- Interests
- Industry funded
- Interests
- Industry funded
Study record
- Design
- crossover trial
- Species
- human
- Population
- Type 2 diabetic patients aged 50-79 years with LDL-C of at least 2.9 mmol/L, Shanghai
- Participants
- 73
- Comparator
- placebo
- Duration
- 84 days
- Endpoints measured
- 23